Russian diabetes market to grow to $1.7 billion
pharmafile | October 17, 2011 | News story | Sales and Marketing | Russia, diabetes
Russia’s diabetes market is set be worth $1.7 billion by 2015, according to a new report.
Industry analysts Decision Resources’ new Type II Diabetes in Russia report predicts the market will grow by $500 million over the next four years, driven by the introduction of several premium-priced agents and the increasing use of GLP-1 analogues.
Approved drugs already on the market include Novo Nordisk’s Victoza and Lilly’s Byetta, dipeptidyl peptidase (DPP-4) inhibitors including Merck’s blockbuster Januvia, and insulin analogue mixes, and a number of others are in development.
If industry pipelines come to fruition, 14 new agents could be launched in Russia by 2015, including two drugs in a novel class of sodium glucose cotransporter (SGLT)-2 inhibitors, Bristol-Myers Squibb/AstraZeneca’s dapagliflozin and Johnson & Johnson’s canagliflozin.
Increasing use of both rapid and long acting branded insulin analogues will be aided by Russia’s reimbursement policy, which covers treatment with most insulin products, including the premium-priced long-acting insulin analogues.
Decision Resources Analyst Natalia Reoutova said: “Increasing use of DPP-4 inhibitors and GLP-1 analogues will also lead to greater spending on antidiabetic agents in Russia.
“Most of the increase in patient share for the newer, more expensive non-insulin drug classes is likely to come from the more-affluent working population of type II diabetes patients who pay for their treatment out of pocket, as these drugs are not currently reimbursed.
“It’s possible that the Russian diabetes drug market will grow even more if the government begins to reimburse DPP-IV inhibitors or GLP-1 analogues in the future.”
Ben Adams
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
AOTI diabetic foot care therapy to be used by NHS
Effective from September 2025, AOTI’s Topical Wound Oxygen (TWO2) therapy has been awarded inclusion in …
Recce Pharmaceuticals reports positive phase 2 data for skin infection drug
Recce Pharmaceuticals have announced positive patient data from its phase 2 clinical trial into RECCE …
